• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail


FDA Veterinarian Newsletter 2002 Volume XVI, No VI

Dr. Steven D. Vaughn has been selected to fill the position of Director of FDA's Center for Veterinary Medicine's (CVM's) Office of New Animal Drug Evaluation (ONADE.) Dr. Vaughn assumed the role of ONADE Director on November 3, 2002.

Dr. Vaughn has held positions in both CVM's Office of Surveillance and Compliance (OS&C) and ONADE. He joined CVM in 1987 as a veterinary medical officer in OS&C's Division of Surveillance and in 1991 was promoted to Chief of the Antiparasitic and Physiological Drugs Branch in the Division of Therapeutic Drugs for Food Animals in ONADE. In 1992, Dr. Vaughn became the Director of ONADE's Division of Therapeutic Drugs for Food Animals and has served with distinction as a valued member of the ONADE management team. In recent months, Dr. Vaughn has provided invaluable expertise to the Center on such issues as user fee legislation, activity-based costing, and strategic planning.

Dr. Vaughn earned a D.V.M. degree from the University of Georgia in 1978. He has nine years of clinical practice experience. Dr. Vaughn's appointment comes at a time when the Office of New Animal Drug Evaluation is facing unprecedented challenges. Rapid advances in the field of animal biotechnology, the increasingly prominent issue of antimicrobial resistance, and the potential for user fee and minor use/minor species legislation represent just a few of the many issues facing ONADE.

Dr. Andy Beaulieu has been Acting ONADE Director, and he will now resume his position as the Associate Director for Animal Health Policy and Operations.